The Boston Examiner: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Boston Examiner.

Press releases published on October 2, 2026

16 hours ago

Mayhew Tools Expands Cable Tie Line with Mounting Hole Cable Ties and Mounting Pads

Indeterminate EIN Presswire

18 hours ago

ISEE Announces Strategic Partnership with Holman to Scale Autonomous Yard Truck Deployment

Indeterminate EIN Presswire

Oct. 2, 2026

AION Biosystems Named Quarterfinalist in the 2026 Digital Health & AI Awards

Indeterminate EIN Presswire

Oct. 2, 2026

Medical Affairs Leaders Convene in Boston to Chart the Future of Digital Innovation and Ethics in Healthcare Technology

Indeterminate EIN Presswire

Oct. 2, 2026

Nasser Medical Hospital: Gaza’s Largest Remaining Hospital Has No Syringes Left

Indeterminate EIN Presswire

Oct. 2, 2026

United Planet Announces Newly Elected Officers of Its Board of Directors

Indeterminate EIN Presswire

14 hours ago

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

14 hours ago

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

14 hours ago

Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

14 hours ago

Spyre Therapeutics Announces Grants of Inducement Awards

Indeterminate GlobeNewswire

14 hours ago

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

14 hours ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

14 hours ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

14 hours ago

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Oct. 2, 2026

eCrime Workshops Build Capacity for Adversary Analysis, Threat Modeling, Infrastructure Investigation & Data Exchange

Indeterminate EIN Presswire

Oct. 2, 2026

Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus

Indeterminate GlobeNewswire

Oct. 2, 2026

Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug

Indeterminate GlobeNewswire

Oct. 2, 2026

Candel Therapeutics to Present at the SITC 2026 Annual Meeting

Indeterminate GlobeNewswire

Oct. 2, 2026

Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Indeterminate GlobeNewswire

Oct. 2, 2026

Rapid7 Launches Rapid7 Intelligence to Harness Threat Data Against Attackers

Indeterminate GlobeNewswire